Rather than treating changes as isolated region-by-region effects, the team used network localization to identify where structural and functional alterations tend to emerge within interconnected circuits. This approach frames the brain as a dynamic system, where symptoms and recovery may reflect coordinated shifts across networks rather than single “hot spots.”

The study integrates imaging-based measures of structural connectivity and functional patterns, allowing the investigators to localize ECT-related modifications within specific network neighborhoods. By aligning multiple modalities, the researchers aimed to determine whether structural reorganization and functional changes converge on shared circuit locations, potentially offering a more mechanistic account of clinical benefit.

Such multimodal convergence matters because depression involves widespread disruptions spanning large-scale networks, including systems associated with mood regulation, cognitive control, and self-referential processing. If ECT can repeatedly target the same circuit hubs or communication pathways, that would suggest a route from treatment dose to neural recalibration.

The authors describe network localization as a way to reduce ambiguity common in post-treatment neuroimaging. Instead of asking where the brain “changes,” the analysis asks where in the network topology those changes are most likely to concentrate—information that could improve interpretation across studies and patient variability.

Importantly, the work highlights that ECT-induced alterations may not be uniform across the brain. The findings suggest that specific network substructures could act as anchors for both structural remodeling and functional dynamics, which may relate to symptom improvement.

The study’s results also imply that monitoring therapeutic impact might benefit from circuit-level biomarkers. If reliable network signatures can be detected after treatment, they could support stratification of patients or guide optimization of stimulation parameters.

Finally, by linking structural and functional localization within the same network framework, the research advances a systems-level view of how ECT may “reset” dysregulated communication in depression. As clinical neuroimaging moves toward network neuroscience, these methods may sharpen how future trials evaluate mechanistic endpoints.

Subject of Research: Brain structural and functional alterations in depression induced by electroconvulsive therapy (ECT).

Article Title: Network localization of brain structural and functional alterations induced by electroconvulsive therapy for depression.

Article References: Yao, S., Zhu, DM., Zhu, H. et al. Network localization of brain structural and functional alterations induced by electroconvulsive therapy for depression. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04308-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04308-8

The hallmark of ECT’s efficacy lies in its ability to induce controlled seizures under general anesthesia, which paradoxically leads to marked improvements in psychiatric symptoms, especially in major depressive disorder (MDD) and certain psychotic illnesses. Early clinical observations documented its rapid mood-enhancing effects, but the variability in patient outcomes necessitated a deeper search for biomarkers. These markers are critical not only for improving patient selection and reducing cognitive side effects but also for unraveling the complex pathophysiology of treatment-resistant depression.

A key clinical challenge addressed by the review is the heterogeneity of patient responses. While some patients exhibit dramatic remission, others derive minimal benefit. This variability suggests underlying neurobiological differences. Hence, the authors emphasize the role of clinical parameters such as symptom clusters, illness duration, and comorbidities as initial predictors. More granular clinical features, including baseline cognitive function and psychomotor retardation, are correlated with differential outcomes, hinting at distinct neural circuit involvement and neuroplasticity potential.

Venturing beyond clinical descriptors, the review meticulously catalogues neuroimaging findings as promising biological markers. Structural and functional MRI studies highlight the normalization of aberrant connectivity patterns in the prefrontal cortex, hippocampus, and limbic system post-ECT. Changes in cortical thickness and hippocampal volume appear as reliable correlates of clinical improvement, implicating ECT-triggered neurogenesis and synaptic remodeling. Importantly, resting-state functional connectivity analyses reveal shifts in the default mode network and salience network activity, which may underpin symptom alleviation mechanisms.

Electroencephalography (EEG) has also emerged as an invaluable tool in the biomarker landscape. Alterations in spectral power, particularly increased theta and delta rhythms during seizures, are associated with positive treatment response. Pre-ECT EEG patterns also serve predictive functions; patients exhibiting specific baseline slow-wave activity tend to respond more favorably. This electrophysiological data not only enhances treatment customization but also provides real-time markers to optimize ECT parameters such as stimulus intensity and seizure duration.

At the molecular and cellular biology level, the review synthesizes evidence implicating neurotrophic factors as central mediators of ECT effectiveness. Brain-derived neurotrophic factor (BDNF), known for its role in neuronal survival and synaptic plasticity, increases significantly following therapy. Parallel changes in inflammatory markers suggest an interplay between immune modulation and neuroplastic processes. The authors highlight that ECT’s capacity to modulate neuroinflammation and promote neurogenesis could represent the biological substrate for sustained symptom remission.

Genetic and epigenetic investigations further deepen insight into ECT response variability. Polymorphisms in genes regulating neurotransmitter systems, neurotrophic signaling, and stress response pathways may predict both efficacy and side effect susceptibility. Epigenetic modifications, such as DNA methylation changes in key regulatory genes, are emerging as dynamic biomarkers that could reflect the biological imprint of treatment. These molecular markers pave the way for personalized medicine approaches where genetic profiling informs individualized ECT protocols.

One of the most intriguing advances discussed is the potential for integrating multimodal biomarker data into predictive algorithms. Machine learning techniques applied to clinical scores, neuroimaging metrics, EEG parameters, and molecular profiles demonstrate enhanced accuracy in forecasting ECT outcomes. This multidimensional biomarker strategy marks a pivotal step toward clinical decision support systems, allowing psychiatrists to strike a balance between maximal therapeutic effect and minimal cognitive risk.

Cognitive side effects remain a clinical concern, particularly with bilateral electrode placement. The review outlines how emerging biomarkers could predict cognitive trajectories post-ECT, enabling optimized electrode positioning and dosage tailoring. Functional imaging studies indicate that selective modulation of hippocampal circuits is crucial to preserving memory function, a finding that could guide future technical refinements in ECT administration.

Importantly, the authors advocate for longitudinal biomarker assessments throughout the treatment course, emphasizing the dynamic nature of biological response. Real-time biomarker monitoring could inform adaptive therapy protocols, identifying early responders and non-responders to modify treatment plans in real time. This approach aligns with the evolving paradigm of precision psychiatry that transcends static diagnosis-based frameworks.

The review also discusses the ethical and methodological challenges in biomarker research, including cohort heterogeneity, small sample sizes, and technical variability across centers. Standardization of protocols and international consortia for data sharing are proposed as solutions to accelerate biomarker validation and ultimately clinical translation. Moreover, integrating patient-reported outcomes and functional measures complements biological markers for a holistic picture of treatment impact.

Looking ahead, the synthesis provided in this narrative review sets the stage for innovative clinical trials that incorporate biomarker-guided stratification. The emerging biomarker profiles could identify novel therapeutic targets and facilitate combination strategies, such as augmenting ECT with pharmacotherapy or brain stimulation techniques tailored to individual biological profiles. Such synergistic approaches promise to enhance clinical efficacy while mitigating adverse effects.

In conclusion, the comprehensive evaluation of clinical and biological markers reviewed by Zilles-Wegner and colleagues represents a major milestone in understanding ECT’s intricate mechanisms. By bridging clinical phenomenology with cutting-edge neuroscience, this work propels the field toward predictive and personalized psychiatry. As technological and computational advancements converge with deeper biological insights, the vision of tailored, efficient, and safe ECT treatments moves within reach, offering hope for millions afflicted by treatment-resistant psychiatric disorders.

Subject of Research: Clinical and biological markers predicting the effectiveness of electroconvulsive therapy in treatment-resistant psychiatric disorders

Article Title: Clinical and biological markers of electroconvulsive therapy effectiveness: a narrative review

Article References:
Zilles-Wegner, D., von Mücke-Heim, IA., Yrondi, A. et al. Clinical and biological markers of electroconvulsive therapy effectiveness: a narrative review. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03900-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03900-2

Electroconvulsive therapy, introduced in the late 1930s, is a medical procedure that involves inducing brief, controlled seizures in the brain through electrical stimulation, typically administered over a course of 6 to 12 sessions. Despite its long history, questions remain unresolved in the psychiatric field regarding precisely how ECT exerts its therapeutic effects, the optimal dosing protocols, and which patient populations may genuinely benefit from the intervention. This ambiguity is compounded by the complex neurobiological mechanisms involved, such as alterations in neurotransmitter systems and neuroplasticity, which remain incompletely understood.

The recent survey targeted a convenience sample of 858 ECT recipients alongside 286 of their relatives and friends from 44 different countries. Conducted between January and September 2024, the data gathered presents a compelling snapshot of participant recall concerning pre-treatment counseling. Notably, most respondents were female, white, and had undergone ECT treatments within the last decade, although some reported experiences dating back as far as the mid-20th century. The primary indications for ECT included severe depression, psychosis and schizophrenia, bipolar disorders, and catatonia, reflecting the diverse clinical contexts in which the therapy is deployed.

A critical finding of the study was the disparity between reported communication of ECT’s benefits versus its risks. Patients were nearly four times more likely to recall being informed that memory problems following ECT were temporary rather than permanent, highlighting a significant minimization of long-term cognitive side effects. Memory impairment remains one of the most controversial and feared consequences of ECT, with evidence pointing to both transient and enduring deficits in autobiographical memory and other cognitive domains. This discrepancy in communicated risks raises profound ethical questions about the adequacy of informed consent and the patient’s capacity to make fully informed decisions.

Moreover, only a small fraction of participants, roughly 12%, remembered being warned about potential cardiac complications related to ECT. Cardiovascular risks, particularly arrhythmias and transient blood pressure changes, have long been recognized but often receive less emphasis during pre-treatment discussions. Similarly, less than a third of respondents were aware of the risks associated with repeated general anesthesia, which is routinely administered during ECT sessions. The neurocognitive effects of multiple anesthetic exposures, especially in vulnerable populations such as the elderly, remain a subject of ongoing research, but current clinical guidelines underscore the importance of disclosing these considerations to patients.

On the other hand, a substantial majority of respondents recalled being told that ECT is highly effective for severe depression and lifesaving in preventing suicide. These claims, while supported by some clinical trials demonstrating rapid symptom relief in treatment-resistant cases, continue to be contested within some psychiatric circles. The complexity of depression’s etiology and individual variability in treatment response complicate such broad generalizations. Additionally, 58% of patients and 53% of relatives reported having been informed that depression is caused by a chemical imbalance in the brain, a widely used but scientifically oversimplified explanation which has faced criticism for misrepresenting the nuanced pathophysiology underlying mood disorders.

Importantly, nearly 60% of respondents judged the information they received before ECT as inadequate, and an additional 17% were uncertain. This reflects a general dissatisfaction with the extent and quality of communication about both benefits and risks. The researchers emphasize that this dissatisfaction is consistent with previous smaller-scale studies, indicating systemic shortcomings in patient education and ethical practice surrounding this contentious intervention. They stress that the probability of informed consent being compromised has significant legal and professional ramifications, especially given the irreversible nature of some adverse effects linked to ECT.

The qualitative feedback from survey participants further underscores the problem of risk minimization. Many recalled messaging that effectively dismissed the possibility of long-term side effects or portrayed ECT as a completely safe and last-resort treatment option. Such framing can generate unrealistic expectations and potentially skew treatment decisions. Clinicians face a difficult balance between advocating for a treatment that may alleviate suffering and ensuring patients understand the full spectrum of consequences. The ethical imperative to provide balanced, evidence-based information is paramount to uphold patients’ autonomy.

The study also highlighted that family members and friends often share a similar recollection of the information given, underscoring the broader impact of communication strategies on support networks. Given that these individuals frequently play a role in treatment decisions and post-procedure care, enhancing transparency and clarity in pre-treatment consultations could improve overall outcomes and patient satisfaction.

Researchers and ethicists alike call for stronger enforcement of comprehensive informed consent protocols in ECT administration. They advocate for regulatory bodies and professional organizations to intervene if medical institutions fail to implement such standards. Transparent communication must include not only immediate side effects but also potential long-term cognitive impairments, legal rights, and the current limitations of scientific knowledge surrounding ECT’s mode of action and efficacy.

This survey’s limitations, primarily its reliance on voluntary self-reporting and retrospective recall, are acknowledged by the authors. Memory biases and dissatisfaction may have influenced responses, and the non-randomized sampling means findings may not be fully generalizable. However, the consistent trends across a sizable, international cohort lend credence to the notion that information asymmetry persists within ECT treatment paradigms.

In conclusion, this extensive survey highlights a pressing need to reevaluate how electroconvulsive therapy is presented to patients and their families. Ethical medical practice demands that providers deliver balanced and comprehensive information that neither exaggerates benefits nor minimizes risks. Only through transparent dialogue can patients provide truly informed consent and participate meaningfully in decisions about this complex and often last-resort psychiatric intervention. As ECT continues to evolve, robust patient-centered communication must remain at the forefront of clinical care and policy development.

Subject of Research: People

Article Title: A large exploratory survey of electroconvulsive therapy recipients, family members and friends: what information do they recall being given

News Publication Date: 14-Aug-2025

Web References: 10.1136/jme-2024-110629

Keywords: Psychiatry